Fort Collins-based St. Renatus gains FDA approval for dental anesthetic

FORT COLLINS — St. Renatus LLC, a Fort Collins-based biopharmaceutical company, has received FDA approval for its first product, a dental anesthetic.

Kovanaze allows dental anesthesia to be administered through a nasal spray without using a needle. It is designed for use in procedures involving most of the upper teeth.

“For more than 100 years, the dental industry has delivered dental anesthesia using a needle injection. Now, through the efforts of a dedicated team, we have developed a revolutionary needle-free method for delivering pulpal anesthesia,” said Steve Merrick, St. Renatus’ chief executive.

SPONSORED CONTENT

Commercial Solar is a big investment, but not an overwhelming one

Solar offers a significant economic benefit for commercial property owners while also positively impacting the environment and offering a path to compliance for new municipal requirements like Energize Denver. A local, experienced solar installer will help you navigate the complexities of commercial solar to achieve financial success for your project.

Kovanaze is intended for use in dentistry as a topical anesthetic, delivered in the nasal cavity to achieve pulpal, or tooth nerve, anesthesia.

St. Renatus was formed in 2008 and has raised approximately $40 million in funding to pursue the development and approval of the nasal mist.